AAD
Author: Willhemenia Loremipsum Special session: Lorem ipsum dolor sit amet Category: Lorem ipsum View all results

Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.

  • Presentation

Botulinum Toxin Therapy: Four Decades of Medical Innovation

Description

The presentation reviews the four-decade evolution of botulinum toxin therapy, starting with historical insights into the discovery of botulism and its initial medical applications in the 1980s. The speaker, a Senior VP at Allergan Aesthetics, outlines milestones in the development of botulinum toxins for various conditions, particularly strabismus and dystonia, and highlights key figures like Alan Scott, who pioneered early clinical studies. The transition from therapeutic to aesthetic uses is explored, showcasing how serendipitous observation led to widespread use for cosmetic treatments. Innovations in dosing, pharmacology, and understanding of the toxins' mechanisms also shaped the field. The FDA's introduction of class labeling and non-interchangeability in 2000 marked a significant regulatory moment, ensuring patient safety amidst a growing number of botulinum products. The speaker emphasizes the importance of incorporating patient feedback into treatment efficacy assessments and hints at future advancements including novel applications, different product formulations, and a focus on improving patient quality of life. Ultimately, the history of botulinum toxin therapy is characterized by continuous innovation, interdisciplinary collaboration, and a commitment to patient-centric care.

View more

Conclusions

  • Botulinum toxin has evolved from a treatment for rare conditions to a widely used aesthetic treatment.
  • Initial therapeutic studies focused on conditions like strabismus and blepharospasm, leading to FDA approvals in the late 1980s.
  • The drug's effectiveness for aesthetic applications was discovered serendipitously during therapeutic treatments.
  • Phenomenon of serendipity has led to both aesthetic uses being developed from therapeutic applications and vice versa.
  • Patient feedback has played a crucial role in expanding indications for botulinum toxin treatments.
  • Regulatory changes have established non-interchangeability among different botulinum toxin products to ensure safety.
  • Ongoing research into the biology and mechanisms of botulinum toxin continues to drive innovation and new therapeutic applications.
  • The introduction of cell-based potency assays reflects a commitment to ethical practices in drug development and an understanding of neurotoxin action.
  • Future directions in botulinum toxin research include expanded indications, enhanced convenience, and a focus on patient-reported outcomes.
  • Scott AB (1980) Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. J.Pediatr.Ophthalmol.Strabismus 17:21-25
  • Scott A. Development of botulinum toxin (Forward). In: Jankovic J, Albanese A, Atassi MZ, Dolly O, Hallett M, Mayer NH, eds. Botulinum Toxin-Therapeutic Clinical Practice and Science. Saunders, 2009:xi-xii
  • Collins CC, Scott AB, O'Meara DM. Elements of the peripheral oculomotor apparatus. Am.J.Optom.Arch.Am.Acad.Optom. 1969;46:510-515
  • Scott AB, Rosenbaum A, Collins CC. Pharmacologic weakening of extraocular muscles. Invest Ophthalmol. 1973;12:924-927
  • Crone RA, de Jong PTVM, Notermans G. Behandlung des nystagmus durch injektion von butulinustoxin in die augenmuskeln. Klin Mbl Augenheilk 1984;184:216-217
  • Scott AB, Honeychurch D, Brin MF (2023) Early development history of Botox (onabotulinumtoxinA). Medicine (Balt.) 102:e32371
  • Scott AB, Fahn S, Brin MF (2023) Treatment of strabismus and blepharospasm with Botox (onabotulinumtoxinA): Development, insights, and impact. Medicine (Balt.) 102:e32374
  • Elston JS, Lee JP (1985) Paralytic strabismus: the role of botulinum toxin. Br.J.Ophthalmol. 69:891-896
  • Elston JS, Lee JP, Powell CM, Hogg C, Clark P (1985) Treatment of strabismus in adults with botulinum toxin A. Br.J.Ophthalmol. 69:718-724
  • Helverston EM: Death to Beauty, the transformative history of Botox: 2024. Available at https://apps.dtic.mil/sti/tr/pdf/ADA359495.pdf. Accessed 2024.03.04
  • Fahn S, List T, Moskowitz C, Brin M, Bressman S, Burke R, Scott A. Double-blind controlled study of botulinum toxin for blepharospasm. Neurology 1985;35:271-272
  • Blitzer A, Brin MF, Fahn S, Lange D, Lovelace RE. Botulinum toxin (BOTOX) for the treatment of "spastic dysphonia" as part of a trial of toxin injections for the treatment of other cranial dystonias. Laryngoscope 1986;96:1300-1301
  • Brin MF, Fahn S, Moskowitz CB, Blitzer A, Friedman A, Shale HM, Greene PE, List T, Lovelace R. Injections of botulinum toxin for the treatment of focal dystonia. Neurology 1986;36:120 (Abstract)
  • Brin MF, Fahn S, Moskowitz C, Friedman A, Shale HM, Greene PE, Blitzer A, List T, Lange D, Lovelace RE. Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm. Mov Disord 1987;2:237-254.
  • Lew MF, Adornato BT, Duane DD, Dykstra DD, Factor SA, Massey JM, Brin MF, Jankovic J, Rodnitzky RL, Singer C, Swenson MR, Tarsy D, Murray JJ, Koller M, Wallace JD. Botulinum toxin type B (BotB): A double-blind, placebo-controlled, safety and efficacy study in cervical dystonia. Neurology 1997;49:701-707.
  • Simpson LL (1979) The action of botulinal toxin. Rev Infect Dis 1:656-662.
  • Simpson LL (1981) Origin, structure, and pharmacological activity of botulinum toxin. Pharmacol Rev 33:155-188.
  • Schiavo G, Poulain B, Rossetto O, Benfenati F, Tauc L, Montecucco C. Tetanus toxin is a zinc protein and its inhibition of neurotransmitter release and protease activity depend on zinc. EMBO J. 1992;11:3577-3583.
  • Schiavo G, Rossetto O, Santucci A, DasGupta BR, Montecucco C. Botulinum neurotoxins are zinc proteins. J.Biol.Chem. 1992;267:23479-23483.
  • Blasi J, Chapman ER, Link E, Binz T, Yamasaki S, De CP, Sudhof TC, Niemann H, Jahn R. Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25. Nature 1993;365:160-163.
  • Schiavo G, Rossetto O, Catsicas S, Delaureto PP, DasGupta BR, Benfenati F, Montecucco C (1993) Identification of the Nerve Terminal Targets of Botulinum Neurotoxin Serotype-A, Serotype-D, and Serotype-E. J Biol Chem 268:23784-23787.
  • Lacy DB, Tepp W, Cohen AC, DasGupta BR, Stevens RC (1998) Crystal structure of botulinum neurotoxin type A and implications for toxicity. Nat Struct Biol 5:898-902.